Granular cells in ameloblastoma exhibit abnormal biological behaviors, particularly synthesis and secretion of protein. Synthesis of signaling molecules is upregulated, but secretion is arrested in some cases, while both are lost in other cases.
Aims: To study the stromal variation and role of stromal–tumour cell interaction in impaired bone formation as well as enhanced bone resorption in ameloblastoma.
Methods and results: Four types of stroma were observed histologically; fibrous, desmoplastic, myxoid and myxoid with hyalinization. Osteoblast and osteoclast were counted using haematoxylin and eosin sections and immunohistochemistry with CD68. After histomorphometric analysis, only fibrous and myxoid types of stroma were distinctly identified. Secreted frizzled‐related peptide (sFRP)‐2, transforming growth factor‐beta 1 and receptor activator of nuclear factor‐κB ligand (RANKL) revealed strong expression in myxoid type compared with the normal stroma. Bone morphogenetic protein (BMP)‐2 was negative in myxoid type, but positive in normal stroma. Fibrous‐type stroma showed weak expression of all antigens except RANKL compared with myxoid type.
Conclusions: The results suggest that stroma does not act only in bone resorption, but also in the suppression of new bone formation. sFRP‐2 is the main factor for impaired bone formation. The expression of markers related to osteoclastogenesis and suppression of osteoblast formation is higher in myxoid‐type than in fibrous‐type stroma. Tumour cells create a favourable environment for impaired bone formation by secreting sFRP‐2 as well as bone resorption by secreting RANKL and interleukin‐6.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.